8-K Announcements
6Material company update
Feb 12, 2026·SEC
Material company update
Jan 12, 2026·SEC
Material company update
Nov 14, 2025·SEC
10x Genomics, Inc.(TXG)Earnings, Financials & Key Ratios
TXG•NASDAQ
$22.74
$2.93B mkt cap·Price updated May 6, 2026
About10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.Show more
- Revenue$643M+5.2%
- EBITDA-$111M+26.5%
- Net Income-$44M+76.2%
- EPS (Diluted)-0.35+77.0%
- Gross Margin69.05%+1.8%
- EBITDA Margin-17.25%+30.2%
- Operating Margin-17.25%+45.8%
- Net Margin-6.77%+77.3%
- ROE-5.78%+77.0%
- ROIC-17.91%+43.2%
- Debt/Equity0.20+70.3%
TXG Key Insights
10x Genomics, Inc. (TXG) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 39.6%
- ✓FCF machine: 20.2% free cash flow margin
- ✓Momentum leader: RS Rating 83 (top 17%)
- ✓Strong 5Y sales CAGR of 16.6%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TXG Price & Volume
10x Genomics, Inc. (TXG) stock price & volume — 10-year historical chart
Loading chart...
TXG Growth Metrics
10x Genomics, Inc. (TXG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years16.55%
3 Years7.57%
TTM5.25%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM76.16%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM76.97%
Return on Capital
10 Years-33.41%
5 Years-18.44%
3 Years-22.48%
Last Year-13.13%
TXG Recent Earnings
10x Genomics, Inc. (TXG) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 9/12 qtrs (75%)
Q1 2026Latest
Feb 12, 2026EPS
$0.13
Est $0.19
+31.6%
Revenue
$166M
Est $160M
+4.0%
Q4 2025
Nov 6, 2025EPS
$0.22
Est $0.07
-214.3%
Revenue
$149M
Est $142M
+4.6%
Q3 2025
Aug 7, 2025EPS
$0.28
Est $0.35
+180.0%
Revenue
$173M
Est $140M
+23.9%
Q2 2025
May 8, 2025EPS
$0.36
Est $0.45
+20.0%
Revenue
$155M
Est $145M
+6.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 12, 2026 | $0.13vs $0.19+31.6% | $166Mvs $160M+4.0% |
| Q4 2025 | Nov 6, 2025 | $0.22vs $0.07-214.3% | $149Mvs $142M+4.6% |
| Q3 2025 | Aug 7, 2025 | $0.28vs $0.35+180.0% | $173Mvs $140M+23.9% |
| Q2 2025 | May 8, 2025 | $0.36vs $0.45+20.0% | $155Mvs $145M+6.6% |
Based on last 12 quarters of dataView full earnings history →
TXG Peer Comparison
10x Genomics, Inc. (TXG) competitors in Life Sciences and Precision Medicine Software — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PACB | 516.17M | 1.71 | -1.60 | -23.19% | -325.8% | -13.95% | 1.33 | |
 ILMN | 21.66B | 142.58 | 26.16 | -0.78% | 19.43% | 32.84% | 0.94 | |
 BRKR | 6.44B | 42.30 | -282 | 2.08% | -0.75% | -1.11% | 0.81 | |
 FLGT | 443.83M | 14.92 | -7.57 | 13.83% | -18.75% | -5.42% | 0.00 | |
 CDNA | 1.08B | 20.94 | -52.35 | 13.79% | -1.98% | -2.61% | 0.06 | |
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 RXRX | 1.53B | 3.43 | -2.38 | 26.92% | -8.44% | -54.32% | 0.07 | |
 SEER | 105.44M | 1.89 | -1.36 | -8.13% | -486.02% | -29.19% | 0.08 |
Compare TXG vs Peers
10x Genomics, Inc. (TXG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TXG Income Statement
10x Genomics, Inc. (TXG) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 71.08M | 146.31M | 245.89M | 298.85M | 490.49M | 516.41M | 618.73M | 610.78M | 642.82M |
| Revenue Growth % | - | 105.83% | 68.06% | 21.53% | 64.13% | 5.28% | 19.81% | -1.28% | 5.25% |
| Cost of Goods Sold | 10.56M | 28.66M | 61.03M | 58.47M | 74.09M | 120.39M | 209.41M | 196.3M | 198.94M |
| COGS % of Revenue | 14.86% | 19.59% | 24.82% | 19.56% | 15.11% | 23.31% | 33.85% | 32.14% | 30.95% |
| Gross Profit | 60.52M▲ 0% | 117.65M▲ 94.4% | 184.86M▲ 57.1% | 240.38M▲ 30.0% | 416.4M▲ 73.2% | 396.02M▼ 4.9% | 409.31M▲ 3.4% | 414.48M▲ 1.3% | 443.88M▲ 7.1% |
| Gross Margin % | 85.14% | 80.41% | 75.18% | 80.44% | 84.89% | 76.69% | 66.15% | 67.86% | 69.05% |
| Gross Profit Growth % | - | 94.39% | 57.12% | 30.03% | 73.23% | -4.89% | 3.36% | 1.26% | 7.09% |
| Operating Expenses | 78.9M | 135.47M | 213.93M | 325.7M | 469.31M | 563.97M | 674.64M | 609.04M | 554.77M |
| OpEx % of Revenue | 110.99% | 92.59% | 87% | 108.99% | 95.68% | 109.21% | 109.04% | 99.71% | 86.3% |
| Selling, General & Admin | 46.74M | 87.94M | 130.83M | 202.33M | 257.56M | 298.3M | 343.33M | 344.34M | 316.13M |
| SG&A % of Revenue | 65.75% | 60.1% | 53.21% | 67.7% | 52.51% | 57.76% | 55.49% | 56.38% | 49.18% |
| Research & Development | 32.16M | 47.54M | 83.1M | 123.38M | 211.75M | 265.67M | 270.33M | 264.7M | 238.63M |
| R&D % of Revenue | 45.25% | 32.49% | 33.79% | 41.28% | 43.17% | 51.45% | 43.69% | 43.34% | 37.12% |
| Other Operating Expenses | 137K | -249K | 0 | 0 | 0 | 0 | 60.98M | 0 | 0 |
| Operating Income | -18.38M▲ 0% | -110.76M▼ 502.8% | -29.07M▲ 73.8% | -85.32M▼ 193.5% | -52.91M▲ 38.0% | -167.94M▼ 217.4% | -265.33M▼ 58.0% | -194.56M▲ 26.7% | -110.89M▲ 43.0% |
| Operating Margin % | -25.85% | -75.7% | -11.82% | -28.55% | -10.79% | -32.52% | -42.88% | -31.85% | -17.25% |
| Operating Income Growth % | - | -502.8% | 73.75% | -193.5% | 37.99% | -217.4% | -57.99% | 26.67% | 43.01% |
| EBITDA | -14.07M | -106.86M | -22M | -66.3M | -24.66M | -134.94M | -221.71M | -150.85M | -110.89M |
| EBITDA Margin % | -19.79% | -73.03% | -8.95% | -22.19% | -5.03% | -26.13% | -35.83% | -24.7% | -17.25% |
| EBITDA Growth % | - | -659.48% | 79.41% | -201.31% | 62.81% | -447.22% | -64.31% | 31.96% | 26.49% |
| D&A (Non-Cash Add-back) | 4.3M | 3.9M | 7.07M | 19.02M | 28.25M | 33.01M | 43.62M | 43.71M | 0 |
| EBIT | -17.93M | -109.99M | -27.95M | -532.79M | -52.85M | -161.5M | -248.73M | -177.7M | -110.89M |
| Net Interest Income | -503K | -1.39M | -274K | -150K | -660K | 6.17M | 16.87M | 18.44M | 20.05M |
| Interest Income | 308K | 1.02M | 2.81M | 1.53M | 206K | 6.65M | 16.91M | 18.45M | 20.05M |
| Interest Expense | 811K | 2.41M | 3.08M | 1.68M | 866K | 476K | 33K | 4K | 0 |
| Other Income/Expense | -366K | -1.63M | -1.96M | -449.15M | -802K | 5.97M | 16.57M | 16.86M | 70.98M |
| Pretax Income | -18.74M▲ 0% | -112.4M▼ 499.7% | -31.03M▲ 72.4% | -534.48M▼ 1622.3% | -53.72M▲ 89.9% | -161.97M▼ 201.5% | -248.76M▼ 53.6% | -177.7M▲ 28.6% | -39.91M▲ 77.5% |
| Pretax Margin % | -26.36% | -76.82% | -12.62% | -178.85% | -10.95% | -31.36% | -40.21% | -29.09% | -6.21% |
| Income Tax | 21K | 87K | 218K | 8.26M | 4.51M | 4.03M | 6.34M | 4.93M | 3.64M |
| Effective Tax Rate % | -0.11% | -0.08% | -0.7% | -1.54% | -8.39% | -2.49% | -2.55% | -2.77% | -9.11% |
| Net Income | -18.76M▲ 0% | -112.48M▼ 499.5% | -31.25M▲ 72.2% | -542.73M▼ 1636.7% | -58.22M▲ 89.3% | -166M▼ 185.1% | -255.1M▼ 53.7% | -182.63M▲ 28.4% | -43.54M▲ 76.2% |
| Net Margin % | -26.39% | -76.88% | -12.71% | -181.61% | -11.87% | -32.15% | -41.23% | -29.9% | -6.77% |
| Net Income Growth % | - | -499.54% | 72.22% | -1636.68% | 89.27% | -185.11% | -53.67% | 28.41% | 76.16% |
| Net Income (Continuing) | -18.76M | -112.48M | -31.25M | -542.73M | -58.22M | -166M | -255.1M | -182.63M | -43.54M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.62▲ 0% | -8.40▼ 418.5% | -0.80▲ 90.5% | -5.37▼ 571.3% | -0.53▲ 90.1% | -1.46▼ 175.5% | -2.18▼ 49.3% | -1.52▲ 30.3% | -0.35▲ 77.0% |
| EPS Growth % | - | -418.52% | 90.48% | -571.25% | 90.13% | -175.47% | -49.32% | 30.28% | 76.97% |
| EPS (Basic) | -1.62 | -8.40 | -0.80 | -5.37 | -0.53 | -1.46 | -2.18 | -1.52 | -0.35 |
| Diluted Shares Outstanding | 11.59M | 13.39M | 39.09M | 101.15M | 110.35M | 113.86M | 117.17M | 120.45M | 124.75M |
| Basic Shares Outstanding | 11.59M | 13.39M | 39.06M | 101.15M | 110.35M | 113.86M | 117.17M | 120.45M | 124.75M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
TXG Balance Sheet
10x Genomics, Inc. (TXG) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 68.11M | 106.24M | 480.84M | 774.37M | 747.59M | 635.03M | 596.02M | 584.39M | 684.45M |
| Cash & Short-Term Investments | 47.86M | 65.08M | 424.17M | 663.6M | 587.45M | 429.98M | 388.69M | 393.4M | 523.41M |
| Cash Only | 47.86M | 65.08M | 424.17M | 663.6M | 587.45M | 219.75M | 359.28M | 344.07M | 473.97M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 210.24M | 29.41M | 49.34M | 49.44M |
| Accounts Receivable | 13.34M | 28.09M | 33.37M | 51.21M | 85.25M | 104.21M | 114.83M | 87.86M | 82.49M |
| Days Sales Outstanding | 68.5 | 70.07 | 49.54 | 62.54 | 63.44 | 73.66 | 67.74 | 52.51 | 46.84 |
| Inventory | 4.84M | 8.57M | 15.27M | 29.96M | 59.97M | 81.63M | 73.71M | 83.11M | 56.34M |
| Days Inventory Outstanding | 167.22 | 109.14 | 91.32 | 187.03 | 295.42 | 247.49 | 128.47 | 154.53 | 103.37 |
| Other Current Assets | 2.07M | 0 | 0 | 16.57M | 1.03M | 19.21M | 18.79M | 20.02M | 22.21M |
| Total Non-Current Assets | 7.5M | 18.07M | 125.08M | 154.97M | 271.24M | 393.94M | 369.12M | 334.25M | 356.91M |
| Property, Plant & Equipment | 6.92M | 11.13M | 48.82M | 119.82M | 230.41M | 359.21M | 344.93M | 309.94M | 287.16M |
| Fixed Asset Turnover | 10.26x | 13.15x | 5.04x | 2.49x | 2.13x | 1.44x | 1.79x | 1.97x | 2.24x |
| Goodwill | 0 | 0 | 0 | 0 | 4.51M | 4.51M | 4.51M | 4.51M | 4.51M |
| Intangible Assets | 0 | 0 | 22.37M | 22.35M | 25.4M | 22.86M | 16.62M | 15.67M | 62.33M |
| Long-Term Investments | 0 | 5.01M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 577K | 1.94M | 53.9M | 12.8M | 10.92M | 7.37M | 3.06M | 4.13M | 2.91M |
| Total Assets | 75.61M▲ 0% | 124.31M▲ 64.4% | 605.92M▲ 387.4% | 929.34M▲ 53.4% | 1.02B▲ 9.6% | 1.03B▲ 1.0% | 965.14M▼ 6.2% | 918.64M▼ 4.8% | 1.04B▲ 13.4% |
| Asset Turnover | 0.94x | 1.18x | 0.41x | 0.32x | 0.48x | 0.50x | 0.64x | 0.66x | 0.62x |
| Asset Growth % | - | 64.41% | 387.43% | 53.38% | 9.63% | 1% | -6.2% | -4.82% | 13.36% |
| Total Current Liabilities | 22.14M | 32.36M | 63.05M | 118.13M | 110.36M | 130.96M | 127.16M | 117.63M | 153.45M |
| Accounts Payable | 5.44M | 8.79M | 13.03M | 4.71M | 17.35M | 21.6M | 15.74M | 12.91M | 12.73M |
| Days Payables Outstanding | 188.13 | 111.97 | 77.91 | 29.4 | 85.48 | 65.49 | 27.43 | 24 | 23.36 |
| Short-Term Debt | 4.22M | 4.19M | 9.88M | 0 | 0 | 0 | 0 | 0 | 10.98M |
| Deferred Revenue (Current) | 1.83M | 2.78M | 4.6M | 6.2M | 5.34M | 7.87M | 13.15M | 20.66M | 23.9M |
| Other Current Liabilities | 6.72M | 9.2M | 15.56M | 21.63M | 40.91M | 29.74M | 33.96M | 41.84M | 63.33M |
| Current Ratio | 3.08x | 3.28x | 7.63x | 6.56x | 6.77x | 4.85x | 4.69x | 4.97x | 4.46x |
| Quick Ratio | 2.86x | 3.02x | 7.38x | 6.30x | 6.23x | 4.23x | 4.11x | 4.26x | 4.09x |
| Cash Conversion Cycle | 47.59 | 67.24 | 62.94 | 220.17 | 273.38 | 255.66 | 168.78 | 183.03 | 126.85 |
| Total Non-Current Liabilities | 165.98M | 311.94M | 122.79M | 72.14M | 90.9M | 92.28M | 96.94M | 90.87M | 91.58M |
| Long-Term Debt | 6.33M | 25.49M | 19.84M | 0 | 0 | 0 | 0 | 0 | 73.38M |
| Capital Lease Obligations | 0 | 0 | 0 | 57.04M | 76.85M | 86.14M | 83.85M | 73.33M | 73.38M |
| Deferred Tax Liabilities | 158.41M | 284.57M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 514K | 771K | 102.12M | 15.1M | 14.05M | 2.98M | 4.28M | 5.03M | -65.67M |
| Total Liabilities | 188.12M | 344.3M | 185.84M | 190.27M | 201.26M | 223.24M | 224.1M | 208.5M | 245.04M |
| Total Debt | 10.56M | 29.68M | 29.72M | 62.98M | 81.98M | 95.18M | 95.37M | 82.61M | 157.74M |
| Net Debt | -37.3M | -35.4M | -394.45M | -600.63M | -505.47M | -124.57M | -263.91M | -261.45M | -316.23M |
| Debt / Equity | - | - | 0.07x | 0.09x | 0.10x | 0.12x | 0.13x | 0.12x | 0.20x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -22.11x | -45.66x | -9.08x | -316.76x | -61.03x | -339.28x | -7537.27x | -44424.00x | - |
| Total Equity | -112.51M▲ 0% | -219.99M▼ 95.5% | 420.08M▲ 291.0% | 739.07M▲ 75.9% | 817.57M▲ 10.6% | 805.74M▼ 1.4% | 741.04M▼ 8.0% | 710.13M▼ 4.2% | 796.33M▲ 12.1% |
| Equity Growth % | - | -95.53% | 290.96% | 75.93% | 10.62% | -1.45% | -8.03% | -4.17% | 12.14% |
| Book Value per Share | -9.71 | -16.43 | 10.75 | 7.31 | 7.41 | 7.08 | 6.32 | 5.90 | 6.38 |
| Total Shareholders' Equity | -112.51M | -219.99M | 420.08M | 739.07M | 817.57M | 805.74M | 741.04M | 710.13M | 796.33M |
| Common Stock | 1K | 1K | 2K | 2K | 2K | 2K | 2K | 2K | 2K |
| Retained Earnings | -118.63M | -231.12M | -262.37M | -805.1M | -863.32M | -1.03B | -1.28B | -1.47B | -1.51B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -15K | -37K | -46K | -50K | 22K | -4.33M | -429K | -493K | 225K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TXG Cash Flow Statement
10x Genomics, Inc. (TXG) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -10.7M | -76.41M | 34.63M | -217.9M | -21.37M | -33.61M | -15.2M | 6.66M | 136.05M |
| Operating CF Margin % | -15.05% | -52.22% | 14.08% | -72.91% | -4.36% | -6.51% | -2.46% | 1.09% | 21.16% |
| Operating CF Growth % | - | -614.17% | 145.32% | -729.27% | 90.19% | -57.24% | 54.78% | 143.85% | 1941.57% |
| Net Income | -18.76M | -112.48M | -31.25M | -542.73M | -58.22M | -166M | -255.1M | -182.63M | -43.54M |
| Depreciation & Amortization | 4.3M | 3.9M | 7.07M | 19.02M | 28.25M | 33.01M | 43.62M | 43.71M | 43.82M |
| Stock-Based Compensation | 1.66M | 2.66M | 13.33M | 48.63M | 95.96M | 136.85M | 166.95M | 140.75M | 109.12M |
| Deferred Taxes | 0 | 251K | 614K | 1.55M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 149K | 1.25M | 101K | 306.02M | 79K | 1.96M | 11.99M | 3.58M | 1.72M |
| Working Capital Changes | 1.95M | 28.02M | 44.76M | -50.38M | -87.44M | -39.42M | 17.34M | 1.25M | 24.94M |
| Change in Receivables | -5.13M | -14.75M | -5.28M | -17.85M | -34.04M | -18.95M | -10.61M | 26.95M | 6.44M |
| Change in Inventory | -2M | -3.73M | -6.7M | -14.6M | -30.13M | -21.19M | 7.87M | -9.78M | 27.95M |
| Change in Payables | 3.03M | 2.59M | 4.9M | -7.77M | 11.08M | 5.86M | -6.02M | -3.35M | -2.13M |
| Cash from Investing | -3.76M | -6.71M | -42.77M | -38.39M | -106.73M | -350.89M | 133.49M | -32.63M | -13.44M |
| Capital Expenditures | -3.76M | -6.71M | -42.77M | -38.39M | -101.28M | -131.66M | -48.6M | -12.39M | -5.93M |
| CapEx % of Revenue | 5.28% | 4.59% | 17.39% | 12.85% | 20.65% | 25.5% | 7.85% | 2.03% | 0.92% |
| Acquisitions | 0 | 0 | 0 | 0 | -5.45M | -4M | 0 | 0 | -9.27M |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -425K | 0 | 0 | 0 | 0 | -923K | -1M | 0 |
| Cash from Financing | 20.58M | 105.37M | 414.59M | 468.91M | 35.3M | 15.82M | 13.67M | 10.91M | 6.8M |
| Debt Issued (Net) | -393K | 18.74M | 0 | -37.1M | -5.03M | -5.41M | -5.81M | 0 | 0 |
| Equity Issued (Net) | 19.88M | 84.83M | 410.82M | 482.27M | 40.33M | 21.23M | 19.48M | 10.91M | 6.8M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -80K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.09M | 1.8M | 3.77M | 23.74M | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 6.11M▲ 0% | 22.23M▲ 263.6% | 406.4M▲ 1728.1% | 212.15M▼ 47.8% | -92.57M▼ 143.6% | -368.72M▼ 298.3% | 131.93M▲ 135.8% | -15.22M▼ 111.5% | 129.9M▲ 953.6% |
| Free Cash Flow | -14.46M▲ 0% | -83.12M▼ 475.0% | -8.14M▲ 90.2% | -256.29M▼ 3048.6% | -122.65M▲ 52.1% | -165.27M▼ 34.7% | -64.72M▲ 60.8% | -5.73M▲ 91.1% | 130.12M▲ 2371.2% |
| FCF Margin % | -20.33% | -56.81% | -3.31% | -85.76% | -25.01% | -32% | -10.46% | -0.94% | 20.24% |
| FCF Growth % | - | -475.01% | 90.21% | -3048.55% | 52.14% | -34.75% | 60.84% | 91.15% | 2371.16% |
| FCF per Share | -1.25 | -6.21 | -0.21 | -2.53 | -1.11 | -1.45 | -0.55 | -0.05 | 1.04 |
| FCF Conversion (FCF/Net Income) | 0.57x | 0.68x | -1.11x | 0.40x | 0.37x | 0.20x | 0.06x | -0.04x | -3.12x |
| Interest Paid | 0 | 1.82M | 2.25M | 1.67M | 1.22M | 841K | 436K | 0 | 0 |
| Taxes Paid | 0 | 6K | 22K | 280K | 8.66M | 3.92M | 4.93M | 5.64M | 2.39M |
TXG Key Ratios
10x Genomics, Inc. (TXG) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -31.24% | -93.64% | -7.48% | -20.45% | -32.98% | -25.17% | -5.78% |
| Return on Invested Capital (ROIC) | - | - | -85.05% | -78% | -17.62% | -25.36% | -34.36% | -31.52% | -17.91% |
| Gross Margin | 85.14% | 80.41% | 75.18% | 80.44% | 84.89% | 76.69% | 66.15% | 67.86% | 69.05% |
| Net Margin | -26.39% | -76.88% | -12.71% | -181.61% | -11.87% | -32.15% | -41.23% | -29.9% | -6.77% |
| Debt / Equity | - | - | 0.07x | 0.09x | 0.10x | 0.12x | 0.13x | 0.12x | 0.20x |
| Interest Coverage | -22.11x | -45.66x | -9.08x | -316.76x | -61.03x | -339.28x | -7537.27x | -44424.00x | - |
| FCF Conversion | 0.57x | 0.68x | -1.11x | 0.40x | 0.37x | 0.20x | 0.06x | -0.04x | -3.12x |
| Revenue Growth | - | 105.83% | 68.06% | 21.53% | 64.13% | 5.28% | 19.81% | -1.28% | 5.25% |
TXG SEC Filings & Documents
10x Genomics, Inc. (TXG) SEC filings — annual & quarterly reports (10-K, 10-Q)
TXG Frequently Asked Questions
10x Genomics, Inc. (TXG) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
10x Genomics, Inc. (TXG) reported $642.8M in revenue for fiscal year 2025. This represents a 804% increase from $71.1M in 2017.
10x Genomics, Inc. (TXG) grew revenue by 5.2% over the past year. This is steady growth.
10x Genomics, Inc. (TXG) reported a net loss of $43.5M for fiscal year 2025.
Dividend & Returns
10x Genomics, Inc. (TXG) has a return on equity (ROE) of -5.8%. Negative ROE indicates the company is unprofitable.
10x Genomics, Inc. (TXG) generated $130.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More TXG
10x Genomics, Inc. (TXG) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates